Is GANX or SPRO more profitable?

SPRO runs the higher net margin — GANX at 0.00% versus SPRO at 17.18%.

How have GANX and SPRO total returns compared?

Over the past 5 years, GANX delivered -25.06% and SPRO delivered -42.70% annualized total return. Past performance doesn't predict future results.

Gain Therapeutics, Inc. (GANX) vs Spero Therapeutics, Inc. (SPRO)

A side-by-side comparison of Gain Therapeutics, Inc. and Spero Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

GANX

Gain Therapeutics, Inc.

$71M

$1.67HealthcareDelayed quote: Oct 6, 2026, 3:34 PM EDT

SPRO

Spero Therapeutics, Inc.

$69M

$1.19HealthcareDelayed quote: Oct 6, 2026, 3:30 PM EDT

Total return — GANX vs SPRO

growth of $100 · dividends reinvested · last 6y

GANX -84.9% (-27.0%/yr)SPRO -93.1% (-36.0%/yr)GANX compounded faster over this window

GANX SPRO

GANX vs SPRO: by the numbers

•GANX is the larger company ($71M vs $69M market cap).
•SPRO is profitable (17.18% net margin) while GANX runs a net loss (0.00%).

Metrics side by side

Valuation

Metric	GANX	SPRO
P/E ratio	N/A	10.78
P/S ratio	N/A	1.60
P/B ratio	6.29	1.55
EV / EBITDA	N/A	3.31
FCF yield	N/A	28.51%

Profitability

Metric	GANX	SPRO
Gross margin	0.00%	100.00%
Operating margin	0.00%	-0.04%
Net margin	0.00%	17.18%
ROE	-178.06%	16.70%
ROIC	-159.24%	13.12%

Growth (annualized)

Metric	GANX	SPRO
Revenue CAGR (5Y)	N/A	22.93%
Total return CAGR (5Y)	-25.06%	-42.70%

Frequently asked

Is GANX or SPRO more profitable?: SPRO runs the higher net margin — GANX at 0.00% versus SPRO at 17.18%.
How have GANX and SPRO total returns compared?: Over the past 5 years, GANX delivered -25.06% and SPRO delivered -42.70% annualized total return. Past performance doesn't predict future results.

Go deeper

Full GANX analysis Full SPRO analysis Interactive comparison tool

Dig into the metrics

Spero Therapeutics P/E ratio Gain Therapeutics ROE Spero Therapeutics ROE Gain Therapeutics operating margin Spero Therapeutics operating margin Gain Therapeutics revenue growth Spero Therapeutics revenue growth Gain Therapeutics free cash flow Spero Therapeutics free cash flow

Gain Therapeutics & Spero Therapeutics appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks Lowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.